São Paulo, October 6, 2025 – Eurofarma, a Brazilian-born pharmaceutical company present in 24 countries and one of the leaders in Latin America, announces the launch in Brazil of Poviztra® and Extensior® — two new brands of weekly biological injectable semaglutide that arrive on the market through a strategic partnership formed with Novo Nordisk, the global leader in this segment.

The initiative represents an important milestone in expanding the reach of innovative treatments for patients throughout Brazil. Through the agreement, Eurofarma will be responsible for the medical promotion and distribution of Poviztra® and Extensior® in Brazilian territory, uniting Eurofarma's strength and its capillarity in medical visitation with the recognition and innovation of safe, effective, and high-quality therapies from Novo Nordisk.

Poviztra® is indicated for the treatment of obesity and overweight with associated comorbidities, while Extensior® is intended for patients with type 2 diabetes. Poviztra® and Extensior® are neither biosimilars nor generics: they are products composed of the high-quality weekly biological injectable semaglutide molecule.

The prices of the new brands will be lower in relation to the original products, maintaining the focus on expanding medical promotion and the adherence of new patients.

“With the partnership to launch Poviztra® and Extensior® on the market, we are the first Brazilian company to distribute and promote innovative semaglutide treatments in our country,” says Renata Campos, CEO of Eurofarma Brazil. “This partnership reflects our dedication to making high-quality treatments more accessible and strengthening our performance in therapeutic areas that matter most to Brazilian patients and healthcare professionals.”

Context: obesity and type 2 diabetes in Brazil
Obesity and diabetes are major public health challenges in Brazil. In the country's capitals, one in four adults lives with obesity, a condition that increases the risk of serious diseases such as heart attack, stroke, and type 2 diabetes. It is estimated that 70% to 80% of the 16 million Brazilians with type 2 diabetes are overweight or obese, a disease that is one of the main risk factors for cardiovascular diseases (such as stroke and acute myocardial infarction), the main cause of non-traumatic amputation, and the main cause of severe renal failure (1-5).

Early diagnosis and continuous treatment of obesity and type 2 diabetes — with lifestyle changes and evidence-based therapies, including GLP-1 receptor agonists when indicated — are essential to reduce complications and improve quality of life (4).

Brazilian Market
A July 2025 survey by IQVIA, the main pharmaceutical market audit, shows that the market for injectable GLP-1 products in Brazil recorded a compound annual growth rate (CAGR) of 39% over the last five years. In the last 12 months (from August 2024 to July 2025), the growth of this market segment in Brazil was 58%.

The market for these products for the treatment of type 2 diabetes and obesity or overweight associated with comorbidities moved more than R$ 6.5 billion in the 12-month period from August 2024 to July 2025, with semaglutide products representing 76% of sales.

References:

1. BRAZIL. Ministry of Health. Vigitel Brasil 2023: surveillance of risk and protection factors for chronic diseases by telephone survey. Brasília: Ministry of Health, 2024. Available at: https://www.gov.br/saude. Accessed on: Sep 15, 2025.
2. INTERNATIONAL DIABETES FEDERATION. IDF Diabetes Atlas. IDF Diabetes Atlas 11th Edition - 2025 | diabetesatlas.org
3. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 Suppl 1):S27-S49.
4. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 Suppl 1):S207-S238.
5. American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 Suppl 1):S167-S180.

About Eurofarma
Founded in 1972, Eurofarma operates in the healthcare sector with the production and marketing of products and services to improve people's quality of life. With a focus on generating shared value, it covers the main pharmaceutical segments, such as medical prescription, generics, hospital, oncology, over-the-counter medicines, personal care, and animal health, in addition to providing production services to third parties. With broad coverage of therapeutic classes, the portfolio comprises more than 4,000 SKUs, serving practically all medical specialties. Leader in medical prescription in Brazil, where it also holds the vice-leadership in generics, Eurofarma is present in 24 countries, with 100% coverage in Latin America and leadership in the region's retail. It also maintains operations in the USA and Africa, counting in total more than 13.5 thousand employees and 11 factories, and accounted for 600 million units produced in 2024. In the same year, the company invested more than R$ 800 million in innovation projects and achieved total net revenue of R$ 11 billion.

Eurofarma Press Office
G&A Relações Públicas
e-mail: imprensaeurofarma@gaspar.com.br
Iza França - 11 97644-4496
Guilherme Gaspar - 11 98285-6000